{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:19:41Z","timestamp":1788391181806,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hoc.2026.05.029","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:27:36Z","timestamp":1788388056000},"page":"705-718","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Understanding the Landscape of Clinically Available Molecular Testing"],"prefix":"10.1016","volume":"40","author":[{"given":"Julia A.","family":"Elvin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.hoc.2026.05.029_bib1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.029_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","author":"Berek","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.hoc.2026.05.029_bib3","unstructured":"American College of Obstetrics and Gynecology. Updated Cervical Cancer Screening Guidelines, April 2021. Available at: https:\/\/www.acog.org\/clinical\/clinical-guidance\/practice-advisory\/articles\/2021\/04\/updated-cervical-cancer-screening-guidelines. Accessed November 2023."},{"issue":"4","key":"10.1016\/j.hoc.2026.05.029_bib4","first-page":"e37509","article-title":"Colon cancer screening methods: 2023 update","volume":"15","author":"Jayasinghe","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.hoc.2026.05.029_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/11769351221076062","article-title":"Liquid biopsy: a distinctive approach to the diagnosis and prognosis of cancer","volume":"21","author":"Hirahata","year":"2022","journal-title":"Cancer Inform"},{"key":"10.1016\/j.hoc.2026.05.029_bib6","series-title":"Diagnostic molecular pathology","article-title":"Molecular testing in breast cancer","author":"Allison","year":"2024"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.029_bib7","doi-asserted-by":"crossref","first-page":"e223833","DOI":"10.1001\/jamanetworkopen.2022.3833","article-title":"Prevalence of UV mutational signatures among cutaneous primary tumors","volume":"5","author":"Mata","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"19","key":"10.1016\/j.hoc.2026.05.029_bib8","first-page":"00248","article-title":"Unique genomic landscape of high-grade neuroendocrine cervical carcinoma: implications for rethinking current treatment paradigms","volume":"4","author":"Eskander","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.029_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/s12885-019-5494-7","article-title":"Identification of candidate cancer predisposing variants by performing whole-exome sequencing on index patients from BRCA1 and BRCA2-negative breast cancer families","volume":"19","author":"Shahi","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.hoc.2026.05.029_bib10","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41591-022-01717-2","article-title":"Delivering precision oncology to patients with cancer","volume":"28","author":"Mateo","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.029_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","article-title":"Quantifying the expanding landscape of clinical actionability for patients with cancer","volume":"14","author":"Suehnholz","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2026.05.029_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/11772719211047763","article-title":"Companion diagnostics: state of the art and new regulations","volume":"16","author":"Valla","year":"2021","journal-title":"Biomark Insights"},{"key":"10.1016\/j.hoc.2026.05.029_bib13","unstructured":"The Role of Lab-Developed Tests in the In Vitro Diagnostics Market, Pew Trusts report, October 22, 2021. Available at: https:\/\/www.pewtrusts.org\/en\/research-and-analysis\/reports\/2021\/10\/the-role-of-lab-developed-tests-in-the-in-vitro-diagnostics-market. Accessed November 2023."},{"issue":"5","key":"10.1016\/j.hoc.2026.05.029_bib14","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3892\/or.2023.8543","article-title":"Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review)","volume":"49","author":"Chen","year":"2023","journal-title":"Oncol Rep"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.029_bib15","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/s41591-023-02226-6","article-title":"A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer","volume":"29","author":"Assaf","year":"2023","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.hoc.2026.05.029_bib16","doi-asserted-by":"crossref","first-page":"11529","DOI":"10.3390\/ijms231911529","article-title":"Comprehensive genomic profiling (CGP)-informed personalized molecular residual disease (MRD) detection: an exploratory analysis from the predator study of metastatic colorectal cancer (mCRC) patients undergoing surgical resection","volume":"23","author":"Lonardi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.hoc.2026.05.029_bib17","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.3390\/cells12121573","article-title":"Circulating tumor DNA in the management of early-stage breast cancer","volume":"12","author":"Vlataki","year":"2023","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.029_bib18","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2026.05.029_bib19","doi-asserted-by":"crossref","first-page":"20913","DOI":"10.1038\/srep20913","article-title":"Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance","volume":"6","author":"Zheng","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.hoc.2026.05.029_bib20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12943-023-01878-9","article-title":"Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study","volume":"22","author":"Bayle","year":"2023","journal-title":"Mol Cancer"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.029_bib21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2217\/fon-2021-1040","article-title":"Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review","volume":"18","author":"Zheng","year":"2022","journal-title":"Future Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.029_bib22","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.029_bib23","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO precision medicine working group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2026.05.029_bib24","doi-asserted-by":"crossref","first-page":"e2200261","DOI":"10.1200\/PO.22.00261","article-title":"Tumor fraction correlates with detection of actionable variants across > 23,000 circulating tumor DNA samples","volume":"6","author":"Husain","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2026.05.029_bib25","doi-asserted-by":"crossref","first-page":"9076","DOI":"10.1200\/JCO.2023.41.16_suppl.9076","article-title":"Utility of ctDNA tumor fraction to inform negative liquid biopsy (LBx) results and need for tissue reflex in advanced non-small cell lung cancer (aNSCLC)","volume":"41","author":"Rolfo","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.029_bib26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/1878-0261.13349","article-title":"Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab","volume":"17","author":"Kansara","year":"2023","journal-title":"Mol Oncol"},{"issue":"22","key":"10.1016\/j.hoc.2026.05.029_bib27","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1158\/1078-0432.CCR-23-1578","article-title":"Circulating tumor DNA monitoring on chemo-immunotherapy for risk stratification in advanced non-small cell lung cancer","volume":"29","author":"Pellini","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.029_bib28","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jamaoncol.2018.2297","article-title":"Prevalence of clonal hematopoiesis mutations in tumor-only clinical genomic profiling of solid tumors","volume":"4","author":"Ptashkin","year":"2018","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1016\/j.hoc.2026.05.029_bib29","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1158\/0008-5472.CAN-22-0985","article-title":"Clonal hematopoiesis of indeterminate potential in patients with solid tumor malignancies","volume":"82","author":"Marshall","year":"2022","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.029_bib30","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","article-title":"Tumor genomic testing for >4,000 men with metastatic castration-resistant prostate cancer in the phase III trial profound (Olaparib)","volume":"28","author":"Hussain","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.029_bib31","doi-asserted-by":"crossref","first-page":"338","DOI":"10.5858\/arpa.2021-0313-OA","article-title":"Method of tissue acquisition affects success of comprehensive genomic profiling in lung cancer","volume":"147","author":"Mata","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.hoc.2026.05.029_bib32","series-title":"Diagnostic molecular biology","article-title":"Amplification of nucleic acids","author":"Shen","year":"2023"},{"key":"10.1016\/j.hoc.2026.05.029_bib33","series-title":"Diagnostic molecular pathology","article-title":"Molecular testing in lung cancer","author":"Shiau","year":"2024"},{"key":"10.1016\/j.hoc.2026.05.029_bib34","series-title":"Diagnostic molecular biology","article-title":"Genome and transcriptome analysis","author":"Shen","year":"2023"},{"key":"10.1016\/j.hoc.2026.05.029_bib35","doi-asserted-by":"crossref","first-page":"e2200454","DOI":"10.1200\/PO.22.00454","article-title":"Proceedings from the ASCO\/college of american pathologists immune checkpoint inhibitor predictive biomarker summit","volume":"6","author":"Hayes","year":"2022","journal-title":"JCO Precis Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000717?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000717?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:01:25Z","timestamp":1788390085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826000717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0889858826000717"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.029","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding the Landscape of Clinically Available Molecular Testing","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}